| Regulatory status | PHASE 3 |
|---|---|
| Mechanism | Triple GIP / GLP-1 / glucagon receptor agonist |
| Form | Lyophilized powder · 10mg, 30mg, 60mg, 100mg |
| CAS | 2381089-83-2 |
| Purity docs | Batch-matched COA available on request — ask us. |
| Ships from | Ontario, Canada |
| Intended use | Laboratory research only. Not for human consumption. |
Retatrutide adds glucagon receptor agonism to the dual incretin backbone — recruiting energy expenditure alongside appetite regulation. In TRIUMPH-1, its phase 3 trial in 2,339 adults with obesity but without diabetes, the 12 mg dose produced 28.3% mean weight loss (70.3 lbs) at 80 weeks — with 45.3% of participants losing at least 30%, a level long associated with bariatric surgery. A two-year extension averaged 30.3%. An FDA filing is expected in Q1 2027.
Lyophilized vials: keep sealed, dry, and away from light and heat. Refrigeration at 2–8°C is the best default; −20°C for long-term storage. After reconstitution: refrigerate at 2–8°C and use promptly — no beyond-use date is validated.
Three receptors, one molecule. The most ambitious incretin in development.
New here? Read the beginner's guide →
$15 flat shipping Canada-wide · free over $200
The active ingredient in Ozempic and Wegovy — the original once-weekly weight-loss medicine.
GLP-1 receptor agonist
The active ingredient in Mounjaro and Zepbound — the newer, stronger once-weekly weight-loss medicine.
Dual GIP / GLP-1 receptor agonist
A once-weekly weight-loss medicine already approved in China — still experimental in Canada and the US.
Dual GLP-1 / glucagon receptor agonist
